Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Organogenesis Holdings (ORGO) Gross Margin (2017 - 2025)

Organogenesis Holdings has reported Gross Margin over the past 9 years, most recently at 43.72% for Q4 2025.

  • Quarterly results put Gross Margin at 43.72% for Q4 2025, down 3176.0% from a year ago — trailing twelve months through Dec 2025 was 61.97% (down 1402.0% YoY), and the annual figure for FY2025 was 61.97%, down 1402.0%.
  • Gross Margin for Q4 2025 was 43.72% at Organogenesis Holdings, down from 75.97% in the prior quarter.
  • Over the last five years, Gross Margin for ORGO hit a ceiling of 78.05% in Q2 2022 and a floor of 43.72% in Q4 2025.
  • Median Gross Margin over the past 5 years was 75.59% (2021), compared with a mean of 73.93%.
  • Biggest five-year swings in Gross Margin: surged 558bps in 2021 and later plummeted -3176bps in 2025.
  • Organogenesis Holdings' Gross Margin stood at 74.51% in 2021, then increased by 3bps to 76.53% in 2022, then fell by -6bps to 72.13% in 2023, then grew by 5bps to 75.48% in 2024, then plummeted by -42bps to 43.72% in 2025.
  • The last three reported values for Gross Margin were 43.72% (Q4 2025), 75.97% (Q3 2025), and 72.64% (Q2 2025) per Business Quant data.